Atea Pharmaceuticals (AVIR) Cash from Investing Activities (2020 - 2026)

Atea Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $29.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 65.26% year-over-year to $29.7 million; the TTM figure through Mar 2026 stood at $132.9 million (up 56.54% YoY), while the FY2025 annual figure was $188.8 million, up 236.5% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $29.7 million, down from $46.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $124.7 million in Q2 2024, with the low at -$487.0 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is $27.8 million (2023), against an average of -$8.3 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities jumped 55736.36% in 2023, then tumbled 112.13% in 2024.
• Atea Pharmaceuticals' Cash from Investing Activities stood at $33.5 million in 2022, then declined by 17.07% to $27.8 million in 2023, then slumped by 112.13% to -$3.4 million in 2024, then surged by 1482.55% to $46.6 million in 2025, then plunged by 36.17% to $29.7 million in 2026.
• Business Quant data shows AVIR's Cash from Investing Activities at $29.7 million in Q1 2026, $46.6 million in Q4 2025, and $41.3 million in Q3 2025.